- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00591682
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
March 24, 2008 updated by: Metastatix, Inc.
Phase I Dose Escalation Study to Determine the Safety and Pharmacokinetics of MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Primary Objectives:
- To determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122
- To characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122
Secondary Objectives:
- To determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122
- To evaluate the preliminary evidence for anti-tumor activity of MSX-122
- To perform correlative studies to elucidate signaling pathways involved in CXCR4 activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA (reverse phase protein microarrays)
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- U.T.M.D. Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with pathologically confirmed advanced malignancy that is metastatic or unresectable and which is refractory to standard therapy or for which there is no standard therapy that provides benefit
- Measurable or non-measurable disease at baseline
- At least four weeks since the last dose of prior chemotherapy, treatment with biologic agents, radiation therapy or investigational agents
- Patients must have recovered from the adverse effects of prior therapy at the time of enrollment to a grade one or less(excluding alopecia)
- Patient will not be treated with any other chemotherapy, immunotherapy, radiotherapy or investigational drug while enrolled on this protocol
- Age >/= 18 year, male or female patients
- Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2
- Life expectancy of greater than 3 months following study entry
- Adequate renal function, defined by serum creatinine less than or equal to 1.5 x ULN
- Adequate hepatic function as defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels </= to 2.5 x ULN and total bilirubin </= to 1.5 x ULN. In the presence of liver metastasis, adequate hepatic function is defined as ALT and AST </= 5 x ULN and total bilirubin </= 3 x ULN. Alkaline phosphatase levels less than or equal to 2.5 x ULN. In the presence of extensive bone metastases, alkaline phosphatase is defined as less than or equal to 5 x ULN
- Adequate bone marrow function as defined by an absolute neutrophil count of >/= 1,500/mm3 (>/=1.5 x 10^9/L), platelet count of >/= 100,000/mm3 (>/=100 x10^9/L) and hemoglobin of >/= 8 gm/dL
- Left ventricular ejection fraction of 50% or greater as measured by echocardiogram or MUGA
- For women of childbearing potential, a negative serum pregnancy test result at screening
- Women of child-bearing potential or men whose sexual partners are women of child-bearing potential must agree to use two methods of adequate contraception (e.g. hormonal and barrier method of birth control) prior to study entry, for the duration of the study, and for 21 days after the last dose of study medication. Acceptable methods of contraception include condoms, diaphragm ,birth control pills, birth control patch, hormonal injections, intrauterine device (IUD), surgical sterilization and/or under the skin implants
- Signed and dated institutional review board (IRB)-approved informed consent before any protocol-specific screening procedures are performed
Exclusion Criteria:
- Patients with uncontrolled concurrent illness, including but not limited to: ongoing or active infection; uncontrolled arterial hypertension (>/= 140/90 mm of mercury on medications); uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder); altered mental status or psychiatric illness/social situations that would limit compliance with study requirements and/or obscure study results
- Patients with a history of a cardiovascular illness including but not confined to: CHF (grade III or IV NYHA); a history of angina pectoris within the previous year; history of any cardiac arrhythmia; QTc prolongation as determined by Bazett's formula and defined as QTc interval >480 msec (including patients on medication which may prolong QTc), or history of myocardial infarction within one year of study enrollment
- Patients with leukemias or myelodysplastic syndrome (MDS)
- Immunocompromised patients, including subjects known to be infected by human immunodeficiency virus (HIV)
- Patients with a history of autologous BMT within the previous five years. Patients with organ transplants, or allogeneic BMT will not be eligible for the study
- Patients with untreated or uncontrolled brain metastasis, or patients with leptomeningeal disease
- Patients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of the oral drugs (e.g. WDHA syndrome, carcinoid syndromes, diarrhea due to infections, malabsorption syndromes secondary to surgery or chemotherapy).
- Patients with a history of major surgery within 28 days of first receipt of study drug
- Nursing or pregnant women
- Patients with any other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding that in the opinion of the investigator, contraindicates the use of an investigational drug, or that may render the patient at excessively high risk for treatment complications
- Patients with a history of one or more other primary carcinomas
- Patients with a known hypersensitivity to any of the components of the drug product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
MSX-122
|
Dosage form = capsule Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122
Time Frame: 12 Months Estimated
|
12 Months Estimated
|
Characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122
Time Frame: 12 Months Estimated
|
12 Months Estimated
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122
Time Frame: 12 Months Estimated
|
12 Months Estimated
|
Evaluate the preliminary evidence for anti-tumor activity of MSX-122
Time Frame: 12 Months Estimated
|
12 Months Estimated
|
Perform correlative studies to elucidate signaling pathways involved in CXCR4 activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA (reverse phase protein microarrays)
Time Frame: 12 Months Estimated
|
12 Months Estimated
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Anticipated)
December 1, 2008
Study Completion (Anticipated)
March 1, 2009
Study Registration Dates
First Submitted
December 31, 2007
First Submitted That Met QC Criteria
December 31, 2007
First Posted (Estimate)
January 11, 2008
Study Record Updates
Last Update Posted (Estimate)
March 26, 2008
Last Update Submitted That Met QC Criteria
March 24, 2008
Last Verified
March 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-0407
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
Clinical Trials on MSX-122
-
TaiwanJ Pharmaceuticals Co., LtdNot yet recruitingNonalcoholic Steatohepatitis (NASH) With Fibrosis
-
Santen Inc.CompletedAge-Related Macular DegenerationUnited States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
CelgeneCompletedClinical Pharmacology, Healthy Male Volunteer StudyUnited States
-
TaiwanJ Pharmaceuticals Co., LtdTerminated
-
CelgeneCompleted
-
CelgeneCompletedRenal InsufficiencyUnited States
-
Bausch Health Americas, Inc.CompletedPlaque PsoriasisUnited States
-
Georgiamune IncRecruitingAdvanced Solid MalignanciesUnited States